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Abstract 
Background: CD4 cells are the major targets for human immunodeficiency virus (HIV) and treatment with Antiretro-
viral Therapy (ART) influences the CD4 cell count of HIV patients. In addition to ART, the time required to reach normal 
range of CD4 counts (500 cells/mm3) can be affected by clinical, socio-demographic, and behavioral factors. This 
retrospective cohort study was conducted to determine the incidence of having the normal range of CD4 cell counts 
and factors that affect the time required to reach this normal range among adult HIV patients who initiated into ART.
Methods: Data of 4 years were retrospectively retrieved from routinely registered characteristics of 937 ART users 
enrolled in 2010. Survival time until immunologic recovery and its determinant factors were examined using the 
frailty model with different parametric distributions alternatively.
Results: Most (80.8%) of the ART attendants had CD4 cell count of 200 cells/mm3 or less at initiation. The overall inci-
dence rate of immunologic recovery was 12.67 persons per 1000 person-months (95% CI 11.30, 14.20). The depend-
ency of frailties of immunologic recovery by residence was statistically significant (Theta = 0.05, p value = 0.006). 
Baseline age (Adjusted Hazard Ratio (AHR) = 0.98, 95% CI 0.97, 0.99), baseline CD4 count (AHR = 1.006, 95% CI 1.005, 
1.008), and female sex (AHR = 1.34, 95% CI 1.03, 1.73) were significantly associated with shorter survival time for 
immunologic recovery.
Conclusion: Higher baseline CD4 count, lower baseline age, and female sex were positively associated with the time 
to immunologic recovery, which also dependent on proximity/residence of ART users. Therefore, further scale up of 
ART services with due emphasis to patients with low CD4 count at baseline particularly for male and older ART users 
are recommended to reach the normal range of CD4 count in a shorter time of treatment.
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Background
Human immunodeficiency virus (HIV) remains a public 
health problem in Ethiopia with an estimated national 
prevalence of 1.14% in 2014 [1]. Out of these patients, 
367,000 were taking Antiretroviral Therapy (ART); 
currently free ART service is available at 1045 health 
facilities in the country [2]. One of these health facili-
ties is Felege Hiwot Referral Hospital which has served 
a large number of patients living in northwestern part 
of the country. For instance, currently about 5575 HIV 
patients are getting ART services in this hospital; 5391 of 
these are adults.
The ART drug changes a fatal disease to a manageable 
chronic illness, and a successful use of ART suppresses 
HIV viral replication, consequently slowing down disease 
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progression, improving immunity, and delaying mortality 
[3]. In general, it has been recommended that it will be 
more effective when initiated as early as possible, specifi-
cally the World Health Organization (WHO) in 2015 rec-
ommended that adults should initiate ART immediately 
after confirming they are positive for the virus irrespec-
tive of their CD4+ T-cell (CD4) count [4].
Nevertheless, because of the high cost of medications 
and treatment, ART drugs are not initiated at the time 
of confirmation of the virus in the blood, especially for 
people in developing countries. For instance, Ethiopia 
set a cutoff point of CD4 cell count of initiating ART for 
adults at 200  cells/mm3 in 2003 and 500  cells/mm3 in 
2014 [2]. It is in the course of time of using the drug that 
their CD4 counts reach, for example, the normal range 
of CD4 counts for the general adult population which 
has a minimum value of 500 cells/mm3 and in this study 
we defined it as immunologic recovery [5]. One of the 
aims of the treatment is to shorten this time and to help 
patients retain their former better immunity level as early 
as possible which is unclear whether this is happening in 
the current study area or not.
However, there are a variety of factors other than HIV 
that could influence the CD4 cell count of human beings. 
For instance, older people have poorer response to ART 
treatment [6, 7]. In addition inaccessibility or distance of 
health facility from residence [8] which can lead to late 
presentation that could affect the disease progression [9, 
10] are the other factors that negatively influence CD4 
count during treatment. Similarly, female sex was nega-
tively associated with CD4 count [10–12] although no 
such association was noted in other studies [6, 13].
For a proper management of treatment, it is vital to 
measure the average length of time from the initiation 
of ART to the time until which the normal range of CD4 
count is retained. It is also important to measure how dif-
ferent variables affect survival time. Therefore, the inci-
dence density of immunologic recovery and the effect of 
socio-demographic and clinical variables on the time to 
immunologic recovery were determined after controlling 
for other variables which are not recorded in the regis-
tration books of adult ART attendants at Felege Hiwot 
Referral Hospital, northwest Ethiopia, by using statistical 
techniques of frailties of immunologic recovery among 
patients.
Methods
Study area and period
The study was conducted at Felege Hiwot Referral Hos-
pital located in Bahir Dar, the capital of the Amhara 
Regional State, Ethiopia. The hospital provides ART ser-
vices to eligible HIV patients in a clinic for both self and 
physician referred patients. The study used data of ART 
attendants enrolled in the first 6 months of the year 2010 
and followed up to mid 2014.
Study design
A retrospective cohort study was conducted to deter-
mine the incidence of having normal range of CD4 cell 
count for the general adult population and factors that 
influence the length of time required to reach this normal 
range among adult HIV patients who initiated ART in the 
hospital.
Study population
All adult HIV positive persons who initiated ART treat-
ment in the hospital from January to June, 2010 (half a 
year) were included in the sample. Therefore, a total of 
937 patients were selected for the sample for analysis. 
During data collection, children aged below 18 years and 
pregnant women were excluded and efforts were made to 
maintain the quality of the data.
Data collection procedures
A pretested structured data collection checklist was 
used to extract routinely recorded data from adult HIV 
patients who initiated ART treatment in the hospital. All 
charts containing detailed data, including the baseline 
CD4 count and repeated measures of CD4 cell counts 
almost every 6  month were reviewed. Similarly, other 
characteristics, like socio-demographic (age and sex), 
clinical (baseline WHO clinical stage, baseline functional 
status), residence, baseline regimen together with others 
were also collected from the registration book of ART 
users.
Five health professionals (B.Sc. Nurses) trained for 
2 days retrieved the data. The principal investigator and 
the supervisor closely monitored the process throughout 
the data collection period and made due corrections.
Survival time was defined as the time starting from the 
date of initiation of ART to the time it reaches the mini-
mum value of the normal range of CD4 count (500 cells/
mm3) determined for each participant. Participants 
who never attained the normal range for different rea-
sons over the follow up period were considered as right 
censored.
Data processing and analysis
The edited and cleaned data were analyzed using the 
statistical software called STATA version 12. The data 
were processed to generate the survival time to reach the 
normal range of CD4 count and the censoring indicator. 
Texts, tables, and graphs were used to show frequencies 
of socio-demographic, clinical, and other variables. The 
survival time until patients’ CD4 count reached normal 
range was also described. Incidence rate of immunologic 
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recovery by each characteristic of patients, including an 
overall incidence rate were determined.
As the study was based on secondary data, all relevant 
independent variables that could affect the survival time 
might not be available. Controlling the effect of these 
unmeasured variables is important to minimize bias on 
the estimate of the effect of existing variables. Therefore, 
the frailty model was employed to determine the adjusted 
effect of available variables on the event of interest after 
controlling for variables not included in the model. The 
effect of unmeasured variables on survival time were 
shared into the residence of participants which was cat-
egorized as remote and close residences, and the statisti-
cal method used was the shared frailty model.
Before using the survival regression models, the 
assumption of proportional hazard was checked using 
the log–log technique. Weibull, exponential, and lognor-
mal distributions were used alternatively to get the fit of 
the baseline hazard. The gamma and inverse Gaussian 
distributions were also used alternatively to represent 
the distribution of frailty. For nested models the likeli-
hood ratio test was used, while for non-nested models 
the Akaike Information Criteria was employed to see the 
fit of data. A p value of 0.05 or less was considered to be 
statistically significant.
Results
Patient characteristics
A total of 937 HIV positive adults who initiated ART 
treatment at Felege Hiwot Referral Hospital were 
included in the study. The average age of the participants 
was 33.7 (95% CI 33.1, 34.3) years; 530 (56.6%) of whom 
were females. Of the participants, 585 (62.4%), lived 
in Bahir Dar (location of hospital) and in neighboring 
towns.
Out of the whole participants, 655 (69.9%) had Base-
line WHO Clinical Stage III and 642 (68.5%) had Work-
ing Functional Status. Including the baseline CD4 count 
measurement, the minimum and maximum numbers of 
CD4 count readings taken from each study participant 
were 1 and 9, respectively. The most important reasons 
for the incompleteness of data or right censoring were 
death, transfer out to other health facilities, and loss to 
follow up (Table 1).
CD4 cell counts
The participants were followed for a total of 23,136 per-
son-months, and 289 (30.8%) participants reached the 
normal range of CD4 count for the general adult popu-
lation (500  cells/mm3 or more) during the follow up 
period. The overall incidence rate of reaching the nor-
mal range of CD4 count was 12.67 persons per 1000 
person-months (95% CI 11.3–14.2). The incidence rate 
of reaching the normal range of CD4 counts among age 
groups of 18–25  years was 17.20 persons per 1000 per-
son-months (95% CI 13.6, 21.9) while it was 4.19 persons 
per 1000 person-months (95% CI 1.8, 9.1) for the age 
groups of 51–71 years. The incidence rate of reaching the 
normal range for individuals from Bahir Dar where the 
hospital is located was about 15.05 persons per 1000 per-
son-months, while for those who came from remote dis-
tricts it was only 7.21 persons per 1000 person-months. 
The incidence rate of reaching the normal range of CD4 
counts for patients who had baseline CD4 counts of lower 
than 200 cells/mm3 were 9.70 persons per 1000 person-
months (95% CI 8.4, 11.1), while it was 44.4 persons per 
person-months (95% CI 16.7, 118.5) for patients with 
baseline CD4 counts of 350–499 cells/mm3 (Table 2).
The cumulative hazard of reaching the normal range 
of CD4 count was higher for females than males (p value 
<0.001). Similarly, participants living in Bahir Dar had a 
Table 1 Characteristics of  ART attendants, Felege Hiwot 
Referral Hospital, 2010–2014
Characteristics Number (%)
Baseline age in year (n = 937)
 18–25 173 (18.5)
 26–30 267 (28.5)
 31–40 332 (35.5)
 41–50 114 (12.2)
 51–71 51 (5.4)
Sex (n = 937)
 Female 530 (56.6)
 Male 407 (43.4)
Residence
 Bahir Dar and neighboring towns 585 (62.4)
 Others 352 (37.6)
Baseline functional status (n = 937)
 Working 642 (68.5)
 Ambulatory 246 (26.3)
 Bedridden 49 (5.2)
Baseline WHO clinical stage (n = 937)
 Stage I 44 (4.7)
 Stage II 133 (14.2)
 Stage III 655 (69.9)
 Stage IV 105 (11.2)
First treatment class (n = 937)
 AZT-3TC 553 (59.0)
 D4t-3TC 29 (3.1)
 D4t (30) 355 (37.9)
Baseline CD4 count in cells/mm3 (n = 937)
 <200 757 (80.8)
 200–349 172 (18.3)
 350–499 8 (0.9)
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higher cumulative hazard of reaching the normal range of 
CD4 count compared to others (p value <0.001) (Fig. 1).
Determinant factors for time to reaching the normal range 
of CD4 count
Before trying to fit the data with any of the models, the 
proportional hazard assumption was checked for each of 
the covariates using the log–log technique, and the results 
were satisfactory to assume the lines were more or less 
parallel. Therefore, six variables including participants’ 
baseline age, sex, baseline CD4 count, baseline functional 
status, baseline WHO clinical stage, and the type of first 
line drug were considered as independent variables.
To account for the effect of unmeasured variables, the 
frailty model was fitted. To meet this aim, the effect of 
unmeasured variables was analyzed by sharing it to the 
categories of residence, Bahir Dar and neighboring towns 
Table 2 Number of  events of  reaching normal range of  CD4 count and  incidence densities by  patient characteristics 
among adult HIV patients who initiated ART in Felege Hiwot Referral Hospital, 2010–2014
Characteristics Person-months Number of events Incidence density per 1000 person-months (95% CI)
Baseline age in year (n = 937)
 18–25 3888 67 17.2 (13.6, 21.9)
 26–30 6174 76 12.3 (9.8, 15.4)
 31–40 8610 111 12.9 (10.7, 15.5)
 41–50 3042 29 9.5 (6.6, 13.7)
 51–71 1470 6 4.2 (1.8, 9.1)
Sex (n = 937)
 Female 12,630 195 15.5 (13.5, 17.8)
 Male 10,554 94 8.9 (7.3, 10.9)
Residence
 Bahir Dar and neighboring towns 15,552 234 15.1 (13.2, 17.1)
 Others 7632 55 7.2 (5.5, 9.4)
Baseline functional status (n = 937)
 Working 17,466 220 12.6 (11.0, 14.4)
 Ambulatory 4830 61 12.6 (9.8, 16.2)
 Bedridden 888 8 9.0 (4.5, 18.0)
Baseline WHO clinical stage (937)
 Stage I 1200 13 10.8 (6.3, 18.7)
 Stage II 3768 35 9.3 (6.7, 12.9)
 Stage III 1598 211 13.2 (11.5, 15.1)
 Stage IV 2232 30 13.4 (9.4, 19.2)
First treatment class (n = 1196)
 AZT-3TC 14,514 166 11.4 (9.8, 13.3)
 D4t-3TC 804 11 13.7 (7.6, 24.7)
 D4t (30) 7866 112 14.2 (11.8,17.1)
Baseline CD4 count in cells/mm3 (n = 1196)
 <200 19,848 192 9.7 (8.4, 11.1)
 200–349 3246 93 28.7 (23.3, 35.1)
 350–499 23,184 4 44.4 (16.7, 118.5)
Fig. 1 Cumulative hazard of reaching the normal range of CD4 
count among ART users in Felege Hiwot Referral Hospital, northwest 
Ethiopia, 2014
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where the hospital is situated on one hand and other 
districts in the catchment area on the other hand. Here, 
residence was preferred on the assumption that it could 
accommodate the effect of different characteristics, like 
accessibility, information, adherence, etc. as individuals 
in the second group were mostly from remote rural areas.
Different techniques of survival analysis were tried to 
find a model that best fits the data. First, the proportional 
hazard model was fitted; then, the Weibull, exponential, 
and log-normal parametric survival models were fitted. 
Finally, with these parametric models, the gamma and 
inverse Gaussian univariate shared frailty models out of 
which the one that gave the best fit was selected were 
fitted.
Accordingly, a model with a baseline hazard of Weibull 
distribution with a shared frailty of gamma distribution 
was selected as the best fit to the data. Thus, three vari-
ables including age, sex, and baseline CD4 count were 
found to be statistically significantly associated with the 
hazard of getting into the normal range of CD4 counts. 
For instance, for each additional age in years, the hazard 
of reaching the normal range of CD4 count decreased by 
2% (AHR = 0.980, 95% CI 0.966, 0.994) (Table 3).
The shape parameter, P, was estimated to be 1.186 (95% 
CI 1.082, 1.299). The dependency of the variability of 
frailties on the categories of residence was also captured 
by the parameter ‘theta’ and was estimated to be 0.0523 
(p value = 0.006).
Discussions
The current study included 937 adult ART users who 
initiated the treatment during the first half year of 2010 
and were followed retrospectively up to mid 2014. For the 
majority of the participants (757 or 80.8%), the baseline 
CD4 count was less than 200 cells/mm3 as it was one of 
the criteria to enroll for ART for HIV positive persons, 
and the remaining persons (180 or 19.2%) could have 
enrolled by other criteria, mostly considering their WHO 
clinical stage. Baseline CD4 count, baseline age, and sex 
were estimated to be determinants of time to immuno-
logic recovery.
The baseline hazard (the effect of time when all cate-
gorical variables are at a reference category and when all 
continuous covariates are at zero) of reaching the normal 
range of CD4 count was fitted with Weibull distribution 
with a shape parameter (P) greater than one (P = 1.186; 
95% CI 1.082, 1.299). The Weibull shape parameter 
greater than one implies that the hazard of immunologic 
recovery increases with time of treatment.
In the analysis of frailty model, residence was taken 
as a clustering variable. The variability of the effect of 
unobserved variables on the time to immunologic recov-
ery was estimated to be significantly different from zero 
(Theta = 0.052, p value = 0.006). This shows that there 
are unmeasured confounders which have a significant 
effect on the time to the event of interest, and the dis-
tribution of these unmeasured variables is different 
between ART users from Bahir Dar city and those who 
come from districts. This could be so probably because 
in addition to being one of the big cities in the country, 
Bahir Dar is a place where the hospital that ART users get 
treatment is located. There could be a suitable condition 
for patients under treatment so that the time required for 
immunologic recovery could be short for patients who 
are residing in the city than others who came from the 
surrounding mostly from rural districts. Different under-
lying and unmeasured characteristics that could affect 
adherence to ART, like accessibility [14–16], information, 
and other societal characteristics that could probably 
affect the time to immunologic recovery could be differ-
ent across such residences.
Baseline CD4 count was positively associated with the 
time to the event of immunologic recovery or reaching 
the normal range of CD4 count for the general adult pop-
ulation (500  cells/mm3). With different statistical meth-
ods, other studies also reached the same conclusion [17, 
18]. This could be of course justifiable because for those 
who had a higher baseline CD4 count, it will be easier 
Table 3 Determinant factors of  time to  reach the normal 
range of  CD4 count among  adult HIV patients who initi-
ated ART in Felege Hiwot Referral Hospital, 2010–2014
P is the shape parameter of Weibull distribution; Theta is the parameter for the 
frailty
Characteristics Hazard ratio (95% CI)
Baseline age in years 0.980 (0.966, 0.9941)
Sex
 Female 1.0
 Male 0.747 (0.577, 0.968)
Baseline functional status
 Working 1.0
 Ambulatory 1.005 (0.742, 1.362)
 Bedridden 0.910 (0.441, 1.879)
Baseline WHO clinical stage
 Stage I 1.0
 Stage II 1.128 (0.593, 2.146)
 Stage III 1.567 (0.887, 2.769)
 Stage IV 1.514 (0.776, 2.952)
First treatment class
 AZT-3TC 1.0
 D4t-3TC 1.223 (0.950, 1.575)
 D4t (30) 1.243 (0.672, 2.298)
Baseline CD4 count 1.006 (1.005, 1.008)
P 1.186 (1.082, 1.299)
Theta 0.052 (0.005, 0.551)
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to reach the normal range as they are closer to the range 
than others who had far a lesser CD4 count. Patients with 
smaller CD4 counts could have a suppressed immunity 
[16] that could make retaining the normal range of CD4 
count difficult for them or they could have co-infections 
which could make the immunologic recovery difficult 
[19].
Baseline age was negatively associated with the time 
required to reach the normal range of CD4 count. Other 
different studies supported this finding [7, 18]. Dif-
ferent authors reasoned out that a favorable influence 
of younger age on CD4 cell recovery while a patient 
is receiving ART may be explained by more-effective 
thymic function [18]. This is because of different bio-
logical characteristics, including immunity that changes 
with age. It was also shown that older persons come to 
the clinic late [15] that could make their response to 
ART treatment poorer [16]. Contrary to these findings, 
other studies reported a null association between age and 
CD4 count increment [13, 19]. This could probably be so 
because the majority of the patients were aged less than 
50 years [13], and 50% of the participants were between 
31 and 41 years of age [19] in the respective studies, and 
in both cases the relative homogeneity in age could dilute 
its effect on CD4 count increment.
In this study, sex was an independent predictor of the 
hazard of reaching CD4 count, specifically, males reduce 
the hazard of reaching normal range of CD4 count almost 
by 25% when compared to females (AHR  =  0.747, 95% 
CI 0.577, 0.968). Other studies were consistent with this 
finding [5, 10]. Contrary to these studies, other authors 
reported that there was no significant difference between 
males and females in response to ART [16, 18]. There 
could be different reasons why a response to ART between 
males and females were different among the studies. One 
justification is that females could attend Voluntary Coun-
seling and Testing as part of their routine health care ser-
vices during pregnancy. As a result, they are more likely 
to be diagnosed for infections earlier than males [20], and 
this could make the response to ART treatment poorer for 
late diagnosed males as their immunity could be weak-
ened. However, early presentation and other related fac-
tors might be indifferent for males and females in the 
studies which reported insignificant associations.
In this study, baseline functional status was not an 
independent predictor of the time to immunologic recov-
ery. However, a study that used longitudinal data analy-
sis showed statistically significant association between 
baseline functional status and CD4 count [21]. Probably, 
this difference could be the distinction in the variables 
predicted by the two studies. The current study predicted 
the time to immunologic recovery while the study done 
in eastern Ethiopia predicted the CD4 count. Therefore, 
functional status may not have any effect on the time to 
reaching the normal range of CD4 count.
As a limitation, because the study was based on sec-
ondary data, information related with some relevant vari-
ables (e.g. nutritional status, substance use, etc.) was not 
available; hence, their effect on the time to immunologic 
recovery was not determined. However, the frailty model 
was used to determine the effect of observed variables 
after controlling for the unmeasured ones.
Conclusion
Higher baseline CD4 count, lower baseline age, and 
female sex were positively associated with time to immu-
nologic recovery of CD4 count. It was also dependent on 
residence of ART users. Therefore, further scale up of 
ART services to be accessible to their residence with due 
emphasis to patients with low CD4 count at baseline par-
ticularly for male and older ART users are recommended 
to reach normal range of CD4 count in shorter time of 
treatment.
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